Event Participants
Executives
3 Beni Prasad Rauka, Mukund Kabra, Ronak Saraf
Analysts
11 Abhishek Kamdar, Abhishek Navalgund, Kethan Chadda, Lakshminarayanan, Nikhil Upadhyay, Ravi Purohit, Rohit Ori, Shayansh Katari, Suryansh, Umang Shah, Zakir Nassar
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹1,898 million | +2% YoY, -7% QoQ; impacted by additional ₹100 million in-transit sales reversal (already recovered post-quarter) |
| EBITDA | ₹510 million | -10% YoY, -19% QoQ; lower realization, elevated power/fuel costs, adverse sales mix |
| EBITDA Margin | 27% | Down 300 bps YoY vs 30% and 400 bps QoQ vs 31%; expected to normalize to ~30% |
| Profit Before Tax | ₹535 million | -2.6% YoY, -10% QoQ; PBT margin ~28% vs 30% in Q1 FY26 |
| Profit After Tax | ₹386 million | -5% YoY, -15% QoQ; PAT margin 20% vs 22% across both comparisons |
| R&D Spend | ₹90 million | 4.75% of revenue vs 4.62% YoY; consolidated R&D at ~5% of total revenue |
| Top 10 Customer Concentration | 23% of revenue | Down from 27% YoY and 26% QoQ; customer diversification improving |
| Working Capital Investment | ₹280 crores | Inventory ₹190 cr, receivables ₹131 cr, payables ₹41 cr; cycle 125–138 days |
| Fermentation Utilization | 70–75% | Approaching capacity threshold; CapEx decision for capacity expansion expected next quarter |
Geographic & Segment Commentary
Human Healthcare: Revenue of ₹1,139 million (-7% YoY, -11% QoQ), contributing 60% of total revenue. Decline driven by lower pharma API sales; B2C revenue in US improved during the quarter. India sales at ₹580 million vs ₹659 million Q1 FY26 and ₹699 million Q4 FY26; international sales at ₹559 million vs ₹562 million Q1 FY26 and ₹582 million Q4 FY26.
Animal Healthcare: Revenue of ₹252 million (-3% YoY, +1% QoQ), contributing 13% of total revenue. Quarterly stability offsets softer YoY base; management flagged expansion into ruminant and animal feed areas.
Bioprocessing: Revenue of ₹306 million (+30% YoY, -5% QoQ), contributing 16% of total revenue. Strong YoY growth driven by healthy food business; biocatalysis contributed ₹45 million in Q4, with second-half growth expected.
Specialized Manufacturing: Revenue of ₹200 million (+41% YoY, +11% QoQ), contributing 11% of total revenue. Continued strong momentum; most rapidly scaling segment of the portfolio.
US / International Markets: US business remains flat with B2C contribution of US$1.14 million vs US$1.12 million YoY. Management transitioning from commodity ingredient sales to branded ingredient positioning for stickier revenue; expects 8–10% growth for the year. USD depreciation (10% YoY) partially masking underlying volumes.
Company-Specific & Strategic Commentary
Buyback and JC Biotech Consolidation: Board approved ₹697 million open-market buyback at ceiling price of ₹500 per share, commencing August 14, 2026. Company acquiring remaining 4.28% stake in JC Biotech for ₹79.79 million, making it a wholly-owned subsidiary. ESOP grants of ~11 lakh shares vesting over five years.
Capacity Expansion: FY27 CapEx guidance of ₹123 crores comprises ₹20 crores maintenance, ₹50 crores R&D facility (functional within next quarter), and balance growth CapEx. Fermentation utilization at 70–75%, prompting potential capacity addition decision in Q2 FY27.
US Branding Strategy: Shifting from pure B2B ingredient supply to co-branded/ingredient-labelled products to increase customer stickiness. Transition is taking time in a challenging geopolitical environment; 70–80% of customer base remains constant with 20–30% churn in any given year.
R&D & Product Pipeline: 15–20 molecules under development at any time; focus areas include protein solubilization, food, animal feed, ruminant, detergent, and biocatalysis. US sugar management patent granted and used for marketing; protein patent granted; biocatalysis patent pending. Algae DHA project (JC Biotech) deprioritized pending new R&D facility.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | Double-digit for FY27 | Q1 implied ~8% including ₹10 crores reversal recovery; management confident on double-digit with strong pipeline and order book |
| EBITDA Margin | ~30% normal level | Expected recovery from 27% in Q1 on operational efficiency, cost optimization, and improved revenue mix |
| US Growth | 8–10% for FY27 | Result of branding transition completion, stabilizing geopolitical environment, and price increases implemented |
| CapEx | ₹123 crores for FY27 | ₹20 crores maintenance, ₹50 crores R&D facility, balance growth; ~₹20 crores spills into Q2 FY27 |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical & Supply Chain Disruption | Global tensions (Iran conflict, trade uncertainty) continue to impact energy pricing and raw material costs, creating volatile operating environment; management expects these to moderate over the year |
| Energy & Power Costs | Elevated power/fuel costs contributed ~300-400 bps of margin compression in Q1; recovery dependent on energy price normalization |
| US Market Transition | Business model shift to branded ingredient sales taking longer than expected; geopolitical situation and hiring challenges have slowed the transition; risk of losing 20–30% churn customers during transition period |
| Regulatory Approvals | Novel food application in Europe remains pending (one prior filing has been waiting since 2014); serratiopeptidase FDC ban impact assessed at ~1% of revenue, not meaningful |
| Currency Depreciation | ~10% YoY USD depreciation impacts reported INR revenue; BAC of ₹131 crores receivables and 125–138 day working capital cycle exposes to collection risk |
Q&A Highlights
FY27 Growth Trajectory and Guidance
Question: Can we close the year at 12%+ given the soft Q1 and the 13–15% three-to-five year target? (Zakir Nassar)
Answer: Management confirmed double-digit growth remains achievable; including ₹10 crores incremental reversal recovery, Q1 implied ~8% growth. Strong momentum expected from Q2 onward. (Beni Prasad Rauka)
Question: Is our business supposed to be recurring with low variability once we're embedded in a customer's process? (Nikhil Upadhyay)
Answer: 70–80% of customers are constant while 20–30% change annually. Quarterly volatility comes from this churn and order timing; sales reversals and inventory adjustments at customer level also create quarterly noise. (Beni Prasad Rauka)
US Business Underperformance
- Question: Over the last 8–9 years US growth has diverged from the 6–7% industry growth - is this internal or external? (Lakshminarayanan)
- Answer: Challenges are multi-factorial: post-COVID stabilization, geopolitical disruptions over last year, and the deliberate shift from commodity ingredient sales to branded ingredient positioning requiring customer-level transition. Company rejected alternate sourcing locations - fermentation will continue in India to remain cost-competitive. (Beni Prasad Rauka)
CapEx and Capacity Utilization
- Question: Is ₹123 crores CapEx for FY27, and what portion is growth CapEx? (Abhishek Navalgund)
- Answer: ₹20 crores is maintenance, ₹50 crores is R&D facility (becoming functional next quarter), balance is growth CapEx. Fermentation utilization has reached 70–75%, prompting a decision on capacity expansion in the next quarter. (Beni Prasad Rauka)
US Brand Strategy Mechanics
- Question: Is the change from B2B to B2C, and how does branding work? (Umang Shah)
- Answer: Business model stays B2B; the change is insisting customer labels include the company's ingredient name on their products, making the business sticky. Once the label is in place, switching costs increase. (Beni Prasad Rauka)
Margin Recovery
- Question: Will EBITDA margins recover to historical levels as energy costs moderate? (Abhishek Kamdar)
- Answer: Management expects EBITDA margins to return to ~30% normal levels as operational efficiency improves and revenue mix normalizes. (Beni Prasad Rauka)
Sales Reversal Accounting
- Question: Can you explain the ₹10 crores incremental sales reversal? (Ravi Purohit)
- Answer: Revenue is recognized when risk and reward transfer to customer; export shipments in transit not yet delivered cannot be recognized. This quarter had an incremental ₹10 crores of such in-transit shipments; material has since reached customers and revenue has been booked. (Mukund Kabra)
Patent Pipeline and New Products
- Question: What is the status of the three patent applications (sugar management, gluten intolerance, biocatalysis) and their revenue potential? (Rohit Ori)
- Answer: US patent granted for sugar management (isomaltulose/sucrase) and for protein; used for marketing advantage. Biocatalysis patent still pending. Sugar management has large market potential alongside GLP-1 studies; protein sales have started this quarter with visibility building in coming quarters. Algae DHA project at JC Biotech is on hold until new R&D facility comes online. (Beni Prasad Rauka)
European Market Growth
- Question: What is driving the ~40% growth in Europe? (Suryansh)
- Answer: Growth driven by the food business through evoxx; quarterly fluctuations in order size should not be extrapolated. Evoxx is primarily an R&D company and revenue should be viewed as more or less flat. Management also expanding into biocatalyst, animal feed, ruminant, and detergent areas. (Unidentified speaker)
Key Takeaway
Advanced Enzyme Technologies delivered a soft Q1 FY27 with revenue of ₹1,898 million (+2% YoY, -7% QoQ), depressed by an incremental ₹100 million in-transit sales reversal that has since been recovered, implying 8% underlying growth. EBITDA margins compressed to 27% (vs 30% YoY) on elevated energy costs and unfavorable mix, with PAT at ₹386 million (-5% YoY). Bioprocessing (+30% YoY) and specialized manufacturing (+41% YoY) drove growth while human healthcare declined 7% YoY on pharma API softness. Management maintained FY27 double-digit revenue guidance and ~30% EBITDA margin recovery, supported by a ₹123 crore CapEx program (70–75% fermentation utilization triggering capacity discussions) and ₹697 million buyback. Strategic priorities include US branding transition targeting 8–10% growth, full acquisition of JC Biotech, and near-term biocatalysis growth. Key watch items include energy cost trajectory, geopolitical disruptions, novel food regulatory approval, and the serratiopeptidase FDC ban impact (1% revenue).